Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methotrexate vs Apremilast in Moderate to Severe Plaque Psoriasis
NCT07337434Phase 1Recruiting
- Start
- Dec 2025
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of apremilast in plaque psoriasis (2 arms). Primary endpoint: Psoriasis Area and Severity Index 75% Reduction at 12 weeks. Started Dec 2025; status: recruiting.
02
Drugs
apremilast
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT07337434.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07337434.